About CxPM

Cx Precision Medicine’s technology is licensed from the University of North Texas Health Science Center (UNTHSC) research laboratory of Sid O’Bryant, PhD, one of the world’s leading experts in blood-based biomarkers for Alzheimer’s Dementia and other neurodegenerative diseases. Dr. O’Bryant is the scientific founder of the company and the Executive Director of the Institute for Translational Research and Dr. Joe and Peggy Schooler Endowed Chair in Pharmacology and Neuroscience at UNTHSC’s Texas School of Osteopathic Medicine. 

The company’s mission is to change expectations for patients suffering from Alzheimer’s and other neurodegenerative diseases by developing tools to accelerate diagnosis, facilitate personalized therapeutic treatment and improve patient outcomes.  We do so by  giving physicians and patients access to better diagnostic tools needed at the primary care level.

Our tests can takes the guesswork out of initial diagnosis of neurodegenerative diseases and represents a paradigm shift to a precision medicine approach, recognizing differences among patients based on their genetics, environment, and lifestyle.

CxPM intellectual properties include 18 issued patents in four patent families.